Structure of a dinitrosyliron complex (DNIC)
In biochemistry , dinitrosyl iron complexes (DNIC' s) are coordination complexes with the formula [Fe(NO)2 (SR)2 ]− . Together with Roussin esters (Fe2 (NO)4 (SR)2 ), they result from the degradation of iron-sulfur proteins by nitric oxide . Commonly the thiolate ligands are cysteinyl residues or glutathione . These metal nitrosyl complexes have attracted much attention because they serve as biochemical signals in response to oxidative stress , manifested in the formation of NO. The anions are tetrahedral.[ 1] [ 2]
References
^ Crack, J. C.; Green, J.; Thomson, A. J.; Brun, N. E. L. (2014). "Iron–Sulfur Clusters as Biological Sensors: The Chemistry of Reactions with Molecular Oxygen and Nitric Oxide". Accounts of Chemical Research . 47 (10): 3196– 3205. doi :10.1021/ar5002507 . PMID 25262769 .
^ Jessica Fitzpatrick; Eunsuk Kim (2015). "Synthetic Modeling Chemistry of Iron–Sulfur Clusters in Nitric Oxide Signaling". Acc. Chem. Res . 48 (8): 2453– 2461. doi :10.1021/acs.accounts.5b00246 . PMID 26197209 .
Forms Targets
NO donors (prodrugs )
NONOates (diazeniumdiolates): Diethylamine/NO (DEA/NO)
Diethylenetriamine/NO (DETA/NO)
GLO/NO
JS-K
Methylamine hexamethylene methylamine/NO (MAHMA/NO)
PROLI/NO
Spermine/NO (SPER/NO)
V-PYRRO/NO
Unsorted: Cimlanod
FK-409
FR144220
FR146881
N-Acetyl-N-acetoxy-4-chlorobenzenesulfonamide
Enzyme (inhibitors )
NOS
nNOS iNOS
1-Amino-2-hydroxyguanidine
2-Ethylaminoguanidine
2-Iminopiperidine
1400W
AEITU
Aminoguanidine (pimagedine)
AMT
AR-C 102222
BYK-191023
Canavanine
Cindunistat (SD-6010)
EITU
IPTU
MITU
N5 -(1-Iminoethyl)-L -ornithine (L -NIO)
N6 -(1-Iminoethyl)-L -lysine (L -NIL)
Nω -Methyl-L -arginine (L -NMA)
Ronopterin (VAS-203)
TRIM
eNOS Unsorted
Arginase CAMK
Others
Precursors: L -Arginine
Nω -Hydroxy-L -arginine (NOHA)
Indirect/downstream NO modulators: ACE inhibitors /AT-II receptor antagonists (e.g., captopril , losartan )
ETB receptor antagonists (e.g., bosentan )
L-Type calcium channel blockers (e.g., dihydropyridines : nifedipine )
Nebivolol (beta blocker )
PDE5 inhibitors (e.g., sildenafil )
non-selective PDE inhibitors (e.g., caffeine )
PDE9 inhibitors (e.g., paraxanthine )
cGMP preferring PDE inhibitors (e.g., sildenafil, paraxanthine, tadalafil)
Statins (e.g., simvastatin )
See also: Receptor/signaling modulators